SEC Form 4 · accession 0001104659-26-104405
Quoin Pharmaceuticals, Ltd. · QNRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Denise P. Carter
Officer — Chief Operating Officer · Director
Period of report
Aug 31, 2026
Accepted (ET)
Sep 1, 2026 · 9:40 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001671502
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ADSsF1 | Aug 31, 2026 | P | 20,490 | $4.88 | A | 37,709 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Warrants (Right to Buy)F2,F3,F4,F1 | $6.10 | Aug 31, 2026 | P | 10,245 | A | Aug 31, 2026 | — | ADS | 10,245 | 10,245 | D |
Explanation of responses
- F1Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
- F2Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.
- F3The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
- F4The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.